Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 50-57

  Oviedo Joekes, Eugenia ^a,b   Guh, Daphne ^b   Brissette, Suzanne ^c   Marchand, Kirsten ^b   Marsh, David ^a,b,d,e   Chettiar, Jill ^b   Nosyk, Bohdan ^b   Krausz, Michael ^a,b   Anis, Aslam ^a,b   Schechter, Martin T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Diacetylmorphine; Gender; Injectable; Methadone; Opioid dependence; Oral; Substitution treatment; Treatment outcome

Indexed keywords

DIAMORPHINE; ILLICIT DRUG; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FAMILY RELATION; FEMALE; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METHADONE TREATMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; WOMEN'S HEALTH;

ADMINISTRATION, ORAL; ADULT; FEMALE; HEALTH STATUS; HEROIN; HUMANS; INJECTIONS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; QUALITY OF LIFE; SEX FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77956187168     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.03.016     Document Type: Article

References (71)

1. Acharyya S., Zhang H. Assessing sex differences on treatment effectiveness from the drug abuse treatment outcome study DATOS. Am. J. Drug Alcohol Abuse 2003, 29:415-444.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV 1994, American Psychiatric Association.
3. Anderson J.F., Warren L.D. Client retention in the British Columbia Methadone Program, 1996-1999. Can. J. Public Health 2004, 95:104-109.
4. Arfken C.L., Klein C., di Menza S., Schuster C.R. Gender differences in problem severity at assessment and treatment retention. J. Subst. Abuse Treat. 2001, 20:53-57.
5. Bennett G.A., Velleman R.D., Barter G., Bradbury C. Gender differences in sharing injecting equipment by drug users in England. AIDS Care 2000, 12:77-87.
6. Booth R.E., Corsi K.F., Mikulich-Gilbertson S.K. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004, 74:177-185.
7. Brady K.T., Randall C.L. Gender differences in substance use disorders. Psychiatr. Clin. North Am. 1999, 22:241-252.
8. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clin. Epidemiol. 1998, 51:1115-1128.
9. Brewer D.D., Fleming C.B., Haggerty K.P., Catalano R.F. Drug use predictors of partner violence in opiate-dependent women. Violence Vict. 1998, 13:107-115.
10. Charney D.A., Palacios-Boix J., Gill K.J. Sexual abuse and the outcome of addiction treatment. Am. J. Addict. 2007, 16:93-100.
11. Chatham L.R., Hiller M.L., Rowan-Szal G.A., Joe G.W., Simpson D.D. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst. Use Misuse 1999, 34:1137-1165.
12. Covington S.S. Women and addiction: a trauma-informed approach. J. Psychoactive Drugs Suppl. 2008, 5:377-385.
13. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51:253-263. discussion 267-268.
14. De Wilde J., Broekaert E., Rosseel Y., Delespaul P., Soyez V. The role of gender differences and other client characteristics in the prevalence of DSM-IV affective disorders among a European therapeutic community population. Psychiatr. Q. 2007, 78:39-51.
15. Des Jarlais D.C., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D.D., McKnight C., Bramson H., Nemeth C., Torian L.V., Friedman S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007, 21:231-235.
16. Erickson P.G., Butters J., Mcgillicuddy P., Hallgren A. Crack and prostitution: gender, myths, and experiences. J. Drug Issues 2000, 30:767-788.
17. Fattore L., Altea S., Fratta W. Sex differences in drug addiction: a review of animal and human studies. Womens Health Lond. Engl. 2008, 4:51-65.
18. Fischer B., Cruz M.F., Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users OPICAN. Can. J. Psychiatry 2006, 51:624-634.
19. Green C.A. Gender and use of substance abuse treatment services. Alcohol Res. Health 2006, 29:55-62.
20. Greenfield S.F., Brooks A.J., Gordon S.M., Green C.A., Kropp F., McHugh R.K., Lincoln M., Hien D., Miele G.M. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007, 86:1-21.
21. Grella C.E. From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J. Psychoactive Drugs Suppl. 2008, 5:327-343.
22. Grella C.E., Karno M.P., Warda U.S., Niv N., Moore A.A. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict. Behav. 2009.
23. Gschwend P., Rehm J., Eschmann S., Uchtenhagen A. Heroin-assisted treatment of opioid addicts in Switzerland from 1994-2001-utilisation and characteristics of admissions and discharges. Gesundheitswesen 2003, 65:75-80.
24. Haasen C., Vertheim U., Degkwitz P., Kuhn S., Ilse J., Lachmann A., Berger J., Schoder V. The German Model Project for Heroin Assisted Treatment of Opioid Dependent Patients. A Multicentric, Randomised, Controlled Treatment Study 2006, Centre for Interdisciplinary Addiction Research of Hamburg University ZIS, Germany.
25. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br. J. Psychiatry 2007, 191:55-62.
26. Hartel D.M., Schoenbaum E.E., Lo Y., Klein R.S. Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection. Clin. Infect. Dis. 2006, 43:525-531.
27. Heading C.E. Gender issues and the pharmacotherapy of substance abuse. IDrugs 2008, 11:428-432.
28. Health Canada Best Practices in Methadone Maintenance Treatment 2002, Minister of Public Works and Government Services Canada, ON, Canada.
29. Hser Y.I., Huang Y., Teruya C., Anglin M.D. Gender differences in treatment outcomes over a three-year period: a path model analysis. J. Drug Issues 2004, 34:419-440.
30. Hser Y.I., Jhosi V., Maglione M., Chou C.P., Anglin M.D. Effects of program and patients characteristics on retention of drug treatment patients. Eval. Program Plann. 2001, 24:331-341.
31. Joe G.W., Simpson D.D., Broome K.M. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 1999, 57:113-125.
32. Jones H.E., Fitzgerald H., Johnson R.E. Males and females differ in response to opioid agonist medications. Am. J. Addict. 2005, 14:223-233.
33. Kerr T., Marsh D., Li K., Montaner J., Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend. 2005, 80:329-335.
34. Kokkevi A., Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur. Addict. Res. 1995, 1:208-210.
35. Liu N., Zhou D., Li B., Ma Y., Hu X. Gender related effects of heroin abuse on the simple reaction time task. Addict. Behav. 2006, 31:187-190.
36. Lynch W.J., Roth M.E., Carroll M.E. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl.) 2002, 164:121-137.
37. Magura S., Nwakeze P.C., Demsky S.Y. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93:51-60.
38. March J.C., Oviedo-Joekes E., Perea-Milla E., Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J. Subst. Abuse Treat. 2006, 31:203-211.
39. Marsden J., Gossop M., Stewart D., Best D., Farrell M., Lehmann P., Edwards C., Strang J. The Maudsley Addiction Profile MAP: a brief instrument for assessing treatment outcome. Addiction 1998, 93:1857-1867.
40. McLellan T.A., Cacciola J.C., Alterman A.I., Rikoon S.H., Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. Am. J. Addict. 2006, 15:113-124.
41. Metrebian N., Shanahan W., Stimson G.V., Small C., Lee M., Mtutu V., Wells B. Prescribing drug of choice to opiate dependent drug users: a comparison of clients receiving heroin with those receiving injectable methadone at a West London drug clinic. Drug Alcohol Rev. 2001, 20:267-276.
42. Mulvaney F.D., Brown L.S., Alterman A.I., Sage R.E., Cnaan A., Cacciola J., Rutherford M. Methadone-maintenance outcomes for Hispanic and African-American men and women. Drug Alcohol Depend. 1999, 54:11-18.
43. Oviedo-Joekes E., Brissette S., Marsh D.C., Lauzon P., Guh D., Anis A., Schechter M.T. Diacetylmorphine versus methadone for the treatment of opioid addiction. N. Engl. J. Med. 2009, 361:777-786.
44. Oviedo-Joekes E., Guh D., Brissette S., Marsh D.C., Nosyk B., Krausz M., Anis A., Schechter M.T. Double-blind Injectable Hydromorphone versus Diacetylmorphine for the treatment of opioid dependence. Journal of Substance Abuse Treatment 2010, 38:408-411.
45. Oviedo-Joekes E., Nosyk B., Brissette S., Chettiar J., Schneeberger P., Marsh D.C., Krausz M., Anis A., Schechter M.T. The North American Opiate Medication Initiative NAOMI: profile of participants in North America's first trial of heroin-assisted treatment. J. Urban Health 2008, 85:812-825.
46. Oviedo-Joekes E., Nosyk B., Marsh D., Guh D., Brissette S., Gartry C., Krausz M., Anis A., Schechter M.T. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. Clin. Trials 2009, 6:261-271.
47. Peles E., Adelson M. Gender differences and pregnant women in a methadone maintenance treatment MMT clinic. J. Addict. Dis. 2006, 25:39-45.
48. Perreault M., Rousseau M., Mercier C., Lauzon P., Gagnon C., Cote P. Accessibility to methadone substitution treatment: the role of a low-threshold program. Can. J. Public Health 2003, 94:197-200.
49. Petry N.M., Bickel W.K. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend. 2000, 58:27-33.
50. Powis B., Griffiths P., Gossop M., Strang J. The differences between male and female drug users: community samples of heroin and cocaine users compared. Subst. Use Misuse 1996, 31:529-543.
51. Puigdollers E., Domingo-Salvany A., Brugal M.T., Torrens M., Alvaros J., Castillo C., Magri N., Martin S., Vazquez J.M. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst. Use Misuse 2004, 39:1353-1368.
52. Rehm J., Frick U., Hartwig C., Gutzwiller F., Gschwend P., Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend. 2005, 79:137-143.
53. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobler-Mikola A., Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001, 358:1417-1423.
54. Ribeaud D. Long-term impacts of the Swiss heroin prescription trials on crime of treated heroin users. J. Drug Issues 2004, 34:163-194.
55. Room R. Heroin maintenance and attraction to treatment. Eur. J. Public Health 2002, 12:234-235.
56. Roth M.E., Cosgrove K.P., Carroll M.E. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci. Biobehav. Rev. 2004, 28:533-546.
57. Rounsaville B.J., Tierney T., Crits-Christoph K., Weissman M.M., Kleber H.D. Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts' problems. Compr. Psychiatry 1982, 23:462-478.
58. Simpson D.D., Joe G.W., Rowan-Szal G.A. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997, 47:227-235.
59. Spitzer D.L. Engendering health disparities. Can. J. Public Health 2005, 96(Suppl. 2):S78-S96.
60. Stewart D., Gossop M., Marsden J., Kidd T., Treacy S. Similarities in outcomes for men and women after drug misuse treatment: results from the National Treatment Outcome Research Study NTORS. Drug Alcohol Rev. 2003, 22:35-41.
61. Tetrault J.M., Desai R.A., Becker W.C., Fiellin D.A., Concato J., Sullivan L.E. Gender and non-medical use of prescription opioids: results from a national US survey. Addiction 2008, 103:258-268.
62. Uphold C.R., Mkanta W.N. Review: use of health care services among persons living with HIV infection: state of the science and future directions. AIDS Patient Care STDS 2005, 19:473-485.
63. van den Brink W., Hendriks V.M., Blanken P., Koeter M.W., van Zwieten B.J., van Ree J.M. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003, 327:310.
64. van der Zanden B.P., Dijkgraaf M.G., Blanken P., de Borgie C.A., van Ree J.M., van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 2006, 82:111-118.
65. Van Etten M.L., Neumark Y.D., Anthony J.C. Male-female differences in the earliest stages of drug involvement. Addiction 1999, 94:1413-1419.
66. Wechsberg W.M., Craddock S.G., Hubbard R.L. How are women who enter substance abuse treatment different than men?: a gender comparison from the Drub Abuse Treatment Outcome Study DATOS. Drugs Soc. 1998, 13:97-115.
67. Weiss S.R., Kung H.C., Pearson J.L. Emerging issues in gender and ethnic differences in substance abuse and treatment. Curr. Womens Health Rep. 2003, 3:245-253.
68. Wetherington C.L. Sex-gender differences in drug abuse: a shift in the burden of proof?. Exp. Clin. Psychopharmacol. 2007, 15:411-417.
69. Zhang Z., Friedmann P.D., Gerstein D.R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003, 98:673-684.
70. Zilberman M., Tavares H., el-Guebaly N. Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. J. Addict. Dis. 2003, 22:61-74.
71. Zilberman M.L., Tavares H., Hodgins D.C., el-Guebaly N. The impact of gender, depression, and personality on craving. J. Addict. Dis. 2007, 26:79-84.